- Home
- INCY vs IREN Comparison
INCY vs IREN Comparison
Compare INCY & IREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | IREN |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 20.3B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INCY | IREN |
|---|---|---|
| Price | $113.21 | $46.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 11 |
| Target Price | ★ $103.52 | $62.50 |
| AVG Volume (30 Days) | 2.0M | ★ 39.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4173.33 | 234.48 |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $3,394,635,000.00 | $501,023,000.00 |
| Revenue This Year | $10.44 | $104.58 |
| Revenue Next Year | $10.99 | $200.20 |
| P/E Ratio | $73.07 | ★ N/A |
| Revenue Growth | 13.67 | ★ 167.65 |
| 52 Week Low | $67.15 | $13.99 |
| 52 Week High | $112.29 | $76.87 |
Technical Indicators
Market Signals| Indicator | INCY | IREN |
|---|---|---|
| Relative Strength Index (RSI) | 68.45 | 38.68 |
| Support Level | $93.60 | $36.43 |
| Resistance Level | N/A | $55.65 |
| Average True Range (ATR) | 4.46 | 4.91 |
| MACD | 0.88 | -1.68 |
| Stochastic Oscillator | 89.55 | 10.51 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About IREN Iris Energy Limited
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.